DDInter624 DDInter413
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997.
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Clopidogrel
Efavirenz {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Clopidogrel
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatic steatosis
Hepatic steatosis {u} (Side Effect) is caused by {v} (Compound) Clopidogrel
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Ticlopidine
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Efavirenz {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is regulated by {v} (Gene) TBXA2R
TBXA2R {u} (Gene) is upregulated by {v} (Compound) Clopidogrel
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatic steatosis
Hepatic steatosis {u} (Side Effect) is caused by {v} (Compound) Tamoxifen
Tamoxifen {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clopidogrel
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Hepatobiliary disease {u} (Side Effect) is caused by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clopidogrel
Efavirenz {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Tapentadol
Tapentadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clopidogrel
Efavirenz {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Ticlopidine
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Efavirenz {u} (Compound) causes {v} (Side Effect) Urinary tract disorder
Urinary tract disorder {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clopidogrel
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Clopidogrel (Compound)
Efavirenz (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Clopidogrel (Compound)
Efavirenz (Compound) causes Hepatic steatosis (Side Effect) and Hepatic steatosis (Side Effect) is caused by Clopidogrel (Compound)
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Ticlopidine (Compound) and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Efavirenz (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is regulated by TBXA2R (Gene) and TBXA2R (Gene) is upregulated by Clopidogrel (Compound)
Efavirenz (Compound) causes Hepatic steatosis (Side Effect) and Hepatic steatosis (Side Effect) is caused by Tamoxifen (Compound) and Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Clopidogrel
Efavirenz (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Fluvastatin (Compound) and Fluvastatin may cause a minor interaction that can limit clinical effects when taken with Clopidogrel
Efavirenz (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Tapentadol (Compound) and Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Efavirenz (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Ticlopidine (Compound) and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Efavirenz (Compound) causes Urinary tract disorder (Side Effect) and Urinary tract disorder (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel